<DOC>
	<DOCNO>NCT01613261</DOCNO>
	<brief_summary>This Multicenter , Open-label , Phase 1b Study TAK-733 Combination With Alisertib Adult Patients With Advanced Nonhematologic Malignancies</brief_summary>
	<brief_title>Study TAK-733 Combination With Alisertib Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male female patient 18 year old Patients must diagnosis solid tumor malignancy standard , curative , lifeprolonging treatment exist longer effective Radiographically clinically evaluable tumor Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Female patient post menopausal least 1 year , surgically sterile , agree practice 2 effective method contraception 30 day last dose study drug agree abstain heterosexual intercourse Male patient agree practice effective barrier contraception 4 month last dose alisertib agree abstain heterosexual intercourse Voluntary write consent Clinical laboratory value specify protocol Female patient breastfeed lactate pregnant Serious medical psychiatric illness laboratory abnormality could , investigator 's opinion , potentially interfere completion treatment accord protocol Treatment investigational product within 28 day first dose study drug Prior treatment Aurora Atargeted agent , include alisertib Prior treatment MEK inhibitor , include TAK733 Prior treatment BRAF inhibitor Systemic anticancer therapy within 21 day first dose Prior biologic immunotherapy within 28 day first dose Major surgery serious infection within 14 day first dose Lifethreatening illness unrelated cancer Known active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C Cardiac condition specify study protocol severe CNS , pulmonary , renal hepatic disease Known GI condition GI procedure could interfere oral absorption tolerance study drug History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness History ongoing newly diagnose eye abnormality Symptomatic brain metastasis Please note additional inclusion exclusion criterion . The study center determine meet criterion . Site personnel explain trial detail answer question may qualify study . You decide whether wish participate . If qualify trial , site personnel explain reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>TAK-733 ,</keyword>
	<keyword>alisertib ,</keyword>
	<keyword>MLN8237 ,</keyword>
	<keyword>Oral MEK Inhibitor ,</keyword>
	<keyword>Oral Aurora A Kinase Inhibitor</keyword>
</DOC>